Search Results - "LUNDE, Laura E"

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma by RICHARDSON, Paul G, WELLER, Edie, WARREN, Diane L, LUNDE, Laura E, MCKENNEY, Mary, DELANEY, Carol, MITSIADES, Constantine S, HIDESHIMA, Teru, DALTON, William, KNIGHT, Robert, ESSELTINE, Dixie-Lee, ANDERSON, Kenneth C, JAGANNATH, Sundar, AVIGAN, David E, ALSINA, Melissa, SCHLOSSMAN, Robert L, MAZUMDER, Amitabha, MUNSHI, Nikhil C, GHOBRIAL, Irene M, DOSS, Deborah

“…Lenalidomide and bortezomib are active in relapsed and relapsed/refractory multiple myeloma (MM). In preclinical studies, lenalidomide sensitized MM cells to…”
Get full text

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma by Richardson, Paul G., Weller, Edie, Lonial, Sagar, Jakubowiak, Andrzej J., Jagannath, Sundar, Raje, Noopur S., Avigan, David E., Xie, Wanling, Ghobrial, Irene M., Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Joyce, Robin, Kaufman, Jonathan L., Doss, Deborah, Warren, Diane L., Lunde, Laura E., Kaster, Sarah, DeLaney, Carol, Hideshima, Teru, Mitsiades, Constantine S., Knight, Robert, Esseltine, Dixie-Lee, Anderson, Kenneth C.

“…This phase 1/2 study is the first prospective evaluation of lenalidomide-bortezomib-dexamethasone in front-line myeloma. Patients (N = 66) received 3-week…”
Get full text

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma by Richardson, Paul G., Xie, Wanling, Jagannath, Sundar, Jakubowiak, Andrzej, Lonial, Sagar, Raje, Noopur S., Alsina, Melissa, Ghobrial, Irene M., Schlossman, Robert L., Munshi, Nikhil C., Mazumder, Amitabha, Vesole, David H., Kaufman, Jonathan L., Colson, Kathleen, McKenney, Mary, Lunde, Laura E., Feather, John, Maglio, Michelle E., Warren, Diane, Francis, Dixil, Hideshima, Teru, Knight, Robert, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Weller, Edie, Anderson, Kenneth C.

“…In this prospective, multicenter, phase 2 study, 64 patients with relapsed or relapsed and refractory multiple myeloma (MM) received up to 8 21-day cycles of…”
Get full text

Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction by Lunde, Laura E., Chuang, Charles, Linden, Michael A., Williams, Sarah A., Sachs, Zohar, Cayci, Zuzan, Young, Jo‐Anne H., Ustun, Celalettin

Get full text

Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival by Lunde, L E, Dasaraju, S, Cao, Q, Cohn, C S, Reding, M, Bejanyan, N, Trottier, B, Rogosheske, J, Brunstein, C, Warlick, E, Young, J A H, Weisdorf, D J, Ustun, C

“…Although hemorrhagic cystitis (HC) is a common complication of allogeneic hematopoietic cell transplantation (alloHCT), its risk factors and effects on…”
Get full text

Phase II Trial of Lenalidomide, Bortezomib, and Dexamethasone In Patients (pts) with Relapsed and Relapsed/Refractory Multiple Myeloma (MM): Updated Efficacy and Safety Data After >2 Years of Follow-up by Richardson, Paul G, Jagannath, Sundar, Jakubowiak, Andrzej J, Lonial, Sagar, Raje, Noopur, Alsina, Melissa, Ghobrial, Irene, Schlossman, Robert L., Mazumder, Amitabha, Munshi, Nikhil C., Vesole, David H., Colson, Kathleen, McKenney, Mary L, Lunde, Laura E, Feather, John, Hideshima, Teru, Knight, Robert D, Esseltine, Dixie-Lee, Mitsiades, Constantine S., Anderson, Kenneth C.

“…Abstract 3049 Single-agent bortezomib (btz) and lenalidomide (len)-dexamethasone (dex) are associated with higher rates of response and improved survival vs…”
Get full text